Busra Nigdelioglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Busra Nigdelioglu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ayberk Bayramgil
Department of Internal Medicine, Istanbul Medipol University, Istanbul 34000, Turkey
1 shared publication - Duygu Yoruk Atik
Department of Nuclear Medicine, Ümraniye Eğitim ve AraştırmaHastanesi, Turkey
1 shared publication - Gülçiçek Ayrancı
Department of Pathology,Ümraniye Eğitim ve Araştırma Hastanesi, Turkey
1 shared publication - Melike Ozcelik
Department of Medical Oncology, Umraniye Education and Research Hospital, University of Health Sciences, Istanbul 34764, Turkey
1 shared publication - Tugce Kubra Gunes
Division of Medical Oncology, Department of Internal Medicine, University of Health Sciences, Istanbul Umraniye Training and Research Hospital, Istanbul 34764, Türkiye
1 shared publication - Özgecan Dülgar
Department of Medical Oncology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey
1 shared publication
Latest Publications
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26 (8) , 1049-1053
Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report
Introduction/Background: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases. Case Presentation: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target. Conclusion: This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26 (8) , 1049-1053
Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report
Introduction/Background: Cholangiocarcinoma (CC) is a rare, aggressive cancer of the bile ducts with limited treatment advancements over recent decades. The five-year survival rate for CC remains low, around 10%, and even lower for advanced cases. Case Presentation: This case report discusses a 46-year-old woman with metastatic CC who achieved remarkable progression-free survival with regorafenib, a multikinase inhibitor typi-cally used in other cancers. After multiple lines of treatment, regorafenib was given as a 7th-line therapy. Despite initial intolerance requiring dose reduction, the patient achieved 22 months of progression-free survival (PFS) with stable disease and partial regression in some areas. Her response to regorafenib significantly exceeded typical outcomes in the literature, where PFS generally ranges from 3 to 4 months. This improvement may be attributed to an FGFR2 mutation identified via next-generation sequencing, which regorafenib may effec-tively target. Conclusion: This case suggests that patients with FGFR2 mutations might benefit from regorafenib, warranting further studies to explore this associationAs can be applied as a promising target gene to develop drug resistance and remedial efficacy.